Core Viewpoint - Ascentage Pharma Group International is set to provide an update on its innovative portfolio and pipeline during an investor webcast, focusing on key presentations at the upcoming 67th American Society of Hematology Annual Meeting [1]. Company Overview - Ascentage Pharma is a global, commercial stage, integrated biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapies for unmet medical needs in cancer [4]. - The company has developed a rich pipeline of innovative drug products, including inhibitors targeting key apoptotic pathway proteins and next-generation kinase inhibitors [4]. Product Pipeline - The first approved product, Olverembatinib, is a third-generation BCR-ABL1 inhibitor for treating chronic myeloid leukemia (CML) with specific mutations and is included in the China National Reimbursement Drug List [5]. - The company is conducting a global registrational Phase III trial (POLARIS-2) for Olverembatinib in CML and additional trials for newly diagnosed Ph+ acute lymphoblastic leukemia (ALL) and SDH-deficient gastrointestinal stromal tumors (GIST) [5]. - The second approved product, Lisaftoclax, is a Bcl-2 inhibitor for various hematologic malignancies and is undergoing multiple global registrational Phase III trials [6]. Research and Development - Ascentage Pharma has established a portfolio of global intellectual property rights and formed partnerships with leading biotechnology and pharmaceutical companies, including Takeda, AstraZeneca, Merck, and Pfizer [7].
Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025